This is the Continuous Integration Build of FHIR (will be incorrect/inconsistent at times).
See the Directory of published versions
Indication example
{
"resourceType" : "ClinicalUseDefinition",
"id" : "example-indication",
"contained" : [{
"resourceType" : "Group",
"id" : "group",
"type" : "person",
"membership" : "definitional",
"characteristic" : [{
"code" : {
"coding" : [{
"system" : "http://ema.europa.eu/example/characteristic",
"code" : "age-range"
}]
},
"valueRange" : {
"low" : {
"value" : 18,
"unit" : "a"
}
},
"exclude" : false
}]
}],
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
"valueCode" : "brr"
}],
"type" : "indication",
"subject" : [{
"reference" : "MedicinalProductDefinition/example"
}],
"indication" : {
"diseaseSymptomProcedure" : {
"concept" : {
"coding" : [{
"system" : "http://ema.europa.eu/example/indicationasdisease-symptom-procedure",
"code" : "Pulmonary-embolism-and-thrombosis-example-code"
}],
"text" : "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."
}
},
"diseaseStatus" : {
"concept" : {
"coding" : [{
"system" : "http://ema.europa.eu/example/diseasestatus",
"code" : "Recurrent"
}]
}
},
"intendedEffect" : {
"concept" : {
"coding" : [{
"system" : "http://ema.europa.eu/example/intendedeffect",
"code" : "PRYLX"
}]
}
}
},
"population" : [{
"reference" : "#group"
}]
}
Usage note: every effort has been made to ensure that the
examples are correct and useful, but they are not a normative part
of the specification.